Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol

Department of Internal Medicine, Uppsala University Hospital, Uppsala, Uppsala, Sweden
British Journal of Haematology (Impact Factor: 4.71). 12/2006; 135(3):367-73. DOI: 10.1111/j.1365-2141.2006.06302.x
Source: PubMed


Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted; 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations.

Download full-text


Available from: Vladimir Lazarevic, Sep 09, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary myelofibrosis is a disease that has been characterized by a number of terms in previous literature. The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) convened in April and November 2006 to clarify definition, response criteria and nomenclature of this condition [1]. The term primary myelofibrosis (PMF) was chosen over several other designations including chronic idiopathic myelofibrosis (CIMF), agnogenic myeloid metaplasia (AMM), and myelofibrosis with myeloid metaplasia (MMM). Myelofibrosis that develops in the setting of either polycythemia vera (PV) or essential thrombocythemia (ET) is referred to as post-PVMFand post-ETMF, respectively, and “leukemic” transformation is now recognized as blast phase disease (PMF-BP, post-PV/ET MF in blast phase). However, the recent change in nomenclature from chronic idiopathic myelofibrosis to primary myelofibrosis [1] is of questionable benefit at best, as well as inexact and confusing, considering that biologically, there is no such thing as “primary” myelofibrosis [2].
    No preview · Article ·
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Haematologica 2012 [Epub ahead of print] Citation: Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, and Beelen DW. DIPSS scores, pre-transplant therapy and chronic GVHD determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012; 97:xxx doi:10.3324/haematol.2011.061168 Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process. Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organiza-tion, and serves the scientific community with strict adherence to the principles of open access publishing ( In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature.
    Full-text · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many techniques have been developed and optimized for processing signals that are corrupted by additive, Gaussian noise. The schemes designed for Gaussian noise typically perform very poorly when the noise is non-Gaussian. An approach for non-Gaussian signal processing is presented in this paper that is based on modeling the probability density function (pdf) of the additive noise with a finite mixture of Gaussian pdfs. Model parameters are estimated using iterative procedures derived from the expectation-maximization (EM) algorithm. Explicit algorithms are presented for several signal processing problems using this framework, including linear regression, array processing, and sequence estimation for intersymbol interference communication channels. The resulting algorithms are data-adaptive, in that they characterize the non-Gaussian noise and then modify the signal processing accordingly.
    No preview · Conference Paper · Dec 1997
Show more